• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patient compliance based on genetic medicine: a literature review.基于基因医学的患者依从性:文献综述
J Community Genet. 2014 Jan;5(1):31-48. doi: 10.1007/s12687-013-0160-2. Epub 2013 Aug 10.
2
Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.遗传性非息肉病性结直肠癌:诊断策略及其影响。
Evid Rep Technol Assess (Full Rep). 2007 May(150):1-180.
3
4
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
7
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.美国临床肿瘤学会政策声明更新:癌症易感性基因检测
J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189. Epub 2003 Apr 11.
8
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.BRCA 突变携带者的双侧预防性乳房切除术:外科医生需要了解的内容。
Ann Ital Chir. 2019;90:1-2.
9
10
Etiology, natural history, management and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): genetic counseling implications.遗传性非息肉病性结直肠癌(林奇综合征)的病因、自然史、管理及分子遗传学:遗传咨询的意义
Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):987-91.

引用本文的文献

1
Patient Perspectives on Personalized Risk Communication Using Polygenic Risk Scores to Inform Colorectal Cancer Screening Decisions.患者对使用多基因风险评分进行个性化风险沟通以指导结直肠癌筛查决策的看法。
AJPM Focus. 2024 Dec 4;4(1):100308. doi: 10.1016/j.focus.2024.100308. eCollection 2025 Feb.
2
Efficacy of polygenic risk scores and digital technologies for INNOvative personalized cardiovascular disease PREVention in high-risk adults: protocol of a randomized controlled trial.多基因风险评分和数字技术在高危成年人创新个性化心血管疾病预防中的疗效:一项随机对照试验的方案。
Front Public Health. 2024 Jun 14;12:1335894. doi: 10.3389/fpubh.2024.1335894. eCollection 2024.
3
Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.临床精神病学中基因检测的障碍及其克服方法:从临床医生的态度到全球患者之间的社会文化差异。
Transl Psychiatry. 2022 Oct 11;12(1):442. doi: 10.1038/s41398-022-02203-6.
4
Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.遗传性癌症综合征风险降低干预措施的系统性障碍:对医疗保健不公平现象的影响。
JCO Precis Oncol. 2021 Nov 3;5. doi: 10.1200/PO.21.00233. eCollection 2021.
5
Communication of cancer-related genetic and genomic information: A landscape analysis of reviews.癌症相关遗传和基因组信息的交流:综述的全景分析。
Transl Behav Med. 2018 Jan 29;8(1):59-70. doi: 10.1093/tbm/ibx063.
6
Knowledge, experiences and attitudes concerning genetics among retinoblastoma survivors and parents.视网膜母细胞瘤幸存者及其父母对遗传学的知识、经验和态度。
Eur J Hum Genet. 2018 Apr;26(4):505-517. doi: 10.1038/s41431-017-0027-9. Epub 2018 Jan 29.
7
Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.遗传性癌症综合征基因检测后的风险管理依从性:新加坡的经验
Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
8
"Where Does it Come from?" Experiences Among Survivors and Parents of Children with Retinoblastoma in Kenya.“它从何而来?”肯尼亚视网膜母细胞瘤患儿幸存者及其父母的经历
J Genet Couns. 2018 Jun;27(3):574-588. doi: 10.1007/s10897-017-0174-8. Epub 2017 Nov 23.
9
Improving Medication Adherence in Coronary Heart Disease.提高冠心病患者的药物依从性
Curr Cardiol Rep. 2017 Sep 22;19(11):113. doi: 10.1007/s11886-017-0918-y.
10
Retail genetics.零售基因检测
Aust Prescr. 2017 Jun;40(3):86-87. doi: 10.18773/austprescr.2017.026. Epub 2017 Jun 1.

本文引用的文献

1
Epidemiology of breast cancer in europe and Africa.欧洲和非洲的乳腺癌流行病学
J Cancer Epidemiol. 2012;2012:915610. doi: 10.1155/2012/915610. Epub 2012 May 27.
2
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis.40 至 49 岁女性乳腺癌的风险因素:系统评价和荟萃分析。
Ann Intern Med. 2012 May 1;156(9):635-48. doi: 10.7326/0003-4819-156-9-201205010-00006.
3
[Life years gained. Long-term trends in mortality by causes of death in Germany and in an international perspective].[获得的生命年数。德国按死因划分的死亡率长期趋势及国际视角]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Apr;55(4):448-58. doi: 10.1007/s00103-012-1455-x.
4
Breast cancer risk factors in Queensland women attending population-based mammography screening.昆士兰州参加基于人群的乳房 X 光筛查的女性的乳腺癌风险因素。
Maturitas. 2012 Mar;71(3):279-86. doi: 10.1016/j.maturitas.2011.12.008. Epub 2012 Jan 4.
5
Direct-to-consumer personalized genomic testing.直接面向消费者的个性化基因组检测。
Hum Mol Genet. 2011 Oct 15;20(R2):R132-41. doi: 10.1093/hmg/ddr349. Epub 2011 Aug 9.
6
Personalized medicine: new genomics, old lessons.个体化医学:新基因组学,旧教训。
Hum Genet. 2011 Jul;130(1):3-14. doi: 10.1007/s00439-011-1028-3. Epub 2011 Jun 26.
7
Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.探讨 DNA 检测在乳腺癌患者中的短期影响:咨询者的看法很重要,但实际的 BRCA1/2 结果并不重要。
Patient Educ Couns. 2012 Feb;86(2):239-51. doi: 10.1016/j.pec.2011.04.017. Epub 2011 Dec 27.
8
Effect of direct-to-consumer genomewide profiling to assess disease risk.直接面向消费者的全基因组分析评估疾病风险的效果。
N Engl J Med. 2011 Feb 10;364(6):524-34. doi: 10.1056/NEJMoa1011893. Epub 2011 Jan 12.
9
Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.快速基因咨询和检测对新诊断乳腺癌患者行为和心理社会影响的多中心随机临床试验设计。
BMC Cancer. 2011 Jan 10;11:6. doi: 10.1186/1471-2407-11-6.
10
Disclosure of individual genetic data to research participants: the debate reconsidered.向研究参与者披露个体基因数据:重新审议该争议。
Trends Genet. 2011 Feb;27(2):41-7. doi: 10.1016/j.tig.2010.11.004. Epub 2010 Dec 27.

基于基因医学的患者依从性:文献综述

Patient compliance based on genetic medicine: a literature review.

作者信息

Schneider Kai Insa, Schmidtke Jörg

机构信息

Institute of Human Genetics, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.

出版信息

J Community Genet. 2014 Jan;5(1):31-48. doi: 10.1007/s12687-013-0160-2. Epub 2013 Aug 10.

DOI:10.1007/s12687-013-0160-2
PMID:23934761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3890067/
Abstract

For this literature review, medical literature data bases were searched for studies on patient compliance after genetic risk assessment. The review focused on conditions where secondary or tertiary preventive options exist, namely cancer syndromes (BRCA-related cancer, HNPCC/colon cancer), hemochromatosis, thrombophilia, smoking cessation, and obesity. As a counterpart, patient compliance was assessed regarding medication adherence and medical advice in some of the most epidemiologically important conditions (including high blood pressure, metabolic syndrome, and coronary heart disease) after receiving medical advice based on nongenetic risk information or a combination of genetic and nongenetic risk information. In the majority of studies based on genetic risk assessments, patients were confronted with predictive rather than diagnostic genetic profiles. Most of the studies started from a knowledge base around 10 years ago when DNA testing was at an early stage, limited in scope and specificity, and costly. The major result is that overall compliance of patients after receiving a high-risk estimate from genetic testing for a given condition is high. However, significant behavior change does not take place just because the analyte is "genetic." Many more factors play a role in the complex process of behavioral tuning. Without adequate counseling and guidance, patients may interpret risk estimates of predictive genetic testing with an increase in fear and anxiety.

摘要

在本次文献综述中,检索了医学文献数据库,以查找有关基因风险评估后患者依从性的研究。该综述聚焦于存在二级或三级预防措施的疾病,即癌症综合征(BRCA相关癌症、遗传性非息肉病性结直肠癌/结肠癌)、血色素沉着症、血栓形成倾向、戒烟和肥胖症。作为对比,在根据非基因风险信息或基因与非基因风险信息组合接受医疗建议后,评估了一些流行病学上最重要疾病(包括高血压、代谢综合征和冠心病)患者在药物依从性和医疗建议方面的依从情况。在大多数基于基因风险评估的研究中,患者面对的是预测性而非诊断性基因图谱。大多数研究始于约10年前的知识库,当时DNA检测尚处于早期阶段,范围和特异性有限且成本高昂。主要结果是,在针对特定疾病进行基因检测获得高风险评估后,患者的总体依从性较高。然而,仅仅因为分析物是“基因的”,并不会发生显著的行为改变。在行为调整的复杂过程中,还有更多因素发挥作用。如果没有充分的咨询和指导,患者可能会带着恐惧和焦虑的增加来解读预测性基因检测的风险评估。